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CLINICAL ARTICLE
Flow diversion technology has revolutionized the treatment of intracranial aneurysms that are subopti-mal for surgical or traditional endovascular interven-
tion.3,12,13,15 While initially approved for large aneurysms in 
the internal carotid artery (ICA), increased safety and fea-
sibility data have allowed for the use of flow diverters in 
progressively varied pathologies and locations.8,17,20,22 The 
braided endoluminal design is intended to occlude aneu-
rysms while maintaining flow through the parent vessel 
and any covered branches.14 Reports of covering critical 
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OBJECTIVE With the increasing use of flow diversion as treatment for intracranial aneurysms, there is a concomitant 
increased vigilance in monitoring complications. The low porosity of flow diverters is concerning when the origins of 
vessels are covered, whether large circle of Willis branches or critical perforators. In this study, the authors report their 
experience with flow diverter coverage of the lenticulostriate vessels and evaluate their safety and outcomes.
METHODS The authors retrospectively reviewed 5 institutional databases of all flow diversion cases from August 2012 
to June 2018. Information regarding patient presentation, aneurysm location, treatment, and outcomes were recorded. 
Patients who were treated with flow diverters placed in the proximal middle cerebral artery (MCA), proximal anterior 
cerebral artery, or distal internal carotid artery leading to coverage of the medial and lateral lenticulostriate vessels were 
included. Clinical outcomes according to the modified Rankin Scale were reviewed. Univariate and multivariate analyses 
were performed to establish risk factors for lenticulostriate infarct.
RESULTS Fifty-two patients were included in the analysis. Postprocedure cross-sectional images were available in 30 
patients. Two patients experienced transient occlusion of the MCA during the procedure; one was asymptomatic, and 
the other had a clinical and radiographic ipsilateral internal capsule stroke. Five patients had transient symptoms without 
radiographic infarct in the lenticulostriate territory. Two patients experienced in-stent thrombosis, leading to clinical MCA 
infarcts (one in the ipsilateral caudate) after discontinuing antiplatelet therapy. Discontinuation of dual antiplatelet therapy 
prior to 6 months was the only variable that was significantly correlated with stroke outcome (p < 0.01, OR 0.3, 95% CI 
0–0.43), and this significance persisted when controlled for other risk factors, including age, smoking status, and aneu-
rysm location.
CONCLUSIONS The use and versatility of flow diversion is increasing, and safety data are continuing to accumulate. 
Here, the authors provide early data on the safety of covering lenticulostriate vessels with flow diverters. The authors 
concluded that the coverage of these perforators does not routinely lead to clinically significant ischemia when dual an-
tiplatelet therapy is continued for 6 months. Further evaluation is needed in larger cohorts and with imaging follow-up as 
experience develops in using these devices in more distal circulation.
https://thejns.org/doi/abs/10.3171/2018.8.JNS18755
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branches and perforators have varied, and practitioners 
are justifiably cautious about deploying these devices over 
critical vessels.
Flow diversion of distal anterior circulation aneurysms 
presents such a challenge. Aneurysms of the proximal 
middle cerebral artery (MCA) and anterior cerebral ar-
tery (ACA) require positioning of the flow diverter (FD) 
so that the device would cover the lateral lenticulostriate 
branches of the MCA or medial lenticulostriate vessels of 
the ACA. Occasionally, flow diversion treatment of distal 
ICA aneurysms (such as anterior choroidal artery [AChA] 
aneurysms) also requires coverage of the lenticulostriate 
vessels. Occlusion of these vessels could lead to clinically 
devastating infarcts. However, certain aneurysms in these 
locations are considered for FD specifically because they 
are not amenable to surgical clipping or endovascular coil-
ing because of their complex fusiform morphology and/or 
giant size. Our previous experience in covering large or es-
sential vessels with FDs did not show clinically significant 
infarcts,26 which is similar to other reports.18,21,23,27,31 Here, 
we present a multicenter experience for treating distal ICA 
aneurysms and proximal MCA and ACA aneurysms with 
the Pipeline embolization device (PED; Medtronic) cover-
ing medial and lateral lenticulostriate vessels.1
Methods
We retrospectively reviewed 5 institutional databases of 
all flow diversion cases from August 2012 to June 2018. 
Cases in which the pathology was in the anterior circula-
tion where the flow diverter either was primarily placed 
or extended into the M1 or A1, covering the lateral or me-dial lenticulostriate branches, respectively, were included. 
Medical records were reviewed for demographic and clini-
cal data. All applicable images were retrospectively re-
viewed when available. Some of the included centers rou-
tinely perform postoperative imaging, while others only 
pursued imaging if there is a change in the patient’s clini-
cal examination findings. The study was approved by each 
local IRB and the IRB of the coordinating center.
Procedure
Senior neurointerventional faculty evaluated the clinical 
presentation and images and formulated the treatment plan 
for all patients. The decision to use FDs as the treatment 
method was based on aneurysm morphology, the presence 
of multiple aneurysms, or surgeon preference. All patients 
were maintained on dual antiplatelet therapy (DAPT; 81 
or 325 mg aspirin and 75 mg clopidogrel) 5 to 7 days prior 
to elective placement of the FD. Appropriate platelet in-
hibition was confirmed when available using the P2Y12 
assay (VerifyNow, Accumetrics) or light transmission ag-
gregometry. An alternative antiplatelet agent was used in 
patients who did not respond to clopidogrel to reduce the 
risk of thromboembolic events.1 A P2Y12 reaction unit of 
≤ 220 or a platelet aggregation < 50% of the maximum 
in 2 runs of 5-μmol/L ADP (adenosine diphosphate) was 
considered to indicate an appropriate level of platelet inhi-
bition for treatment.
Patients received heparin systemically during the pro-
cedure with an activated clotting time ≥ 200 seconds 
throughout the procedure. PEDs were used in all cases and 
delivered in standard fashion. Patients were observed for 
a minimum of 1 night. Images were obtained in patients 
with new neurological symptoms or at the discretion of the 
attending physician. Patients were maintained on aspirin 
and clopidogrel/ticagrelor for at least 3–6 months follow-
ing PED placement and aspirin indefinitely after.
Outcomes
The modified Rankin Scale was used to monitor clini-
cal outcome, and the scores were assessed at baseline, and 
1 day, 3 months, and 6 months postprocedure when avail-
able. Using ipsilateral stroke in the lenticulostriate territory 
as the primary outcome, a Kaplan-Meier survival curve 
was created. Univariate and multivariate analyses were 
performed to assess age, smoking status, aneurysm loca-
tion, and duration of DAPT as risk factors for lenticulo-
striate territory stroke. Exact logistic regression was done 
using Stata (version 15, StataCorp).
Results
Fifty-two patients with aneurysms of the anterior cir-
culation were treated with flow diverters that covered the 
medial or lateral lenticulostriate vessels. Thirty-eight of 
the patients were female, and the mean age was 59 years 
(Table 1). Twenty-three patients had proximal MCA an-
eurysms, 8 had proximal ACA aneurysms, and 21 had 
distal ICA aneurysms where the distal portion of the de-
vice extended into the M1 or A1 segment. Ten patients had previously treated aneurysms, but the aneurysms in the re-
maining patients were incidentally discovered on workup 
for headaches, stroke, or other pathology. Fifteen patients 
had fusiform aneurysms that were not amenable to surgical 
or other endovascular treatment. The mean follow-up was 
14 months. All lenticulostriate vessels were covered by a 
single device.
Imaging Outcomes
Thirty of the 52 patients underwent imaging at some 
point after the procedure. As it is not standard to perform 
imaging in the absence of a change in clinical status, imag-
es included CT scans (n = 11), MR images (n = 15), or both 
(n = 4) and were obtained from 1 day to 4 years postopera-
tively. Thirteen patients underwent imaging within the 1st 
week, with the median time to imaging being 3 months. 
Many of the images were obtained for headache or other 
symptoms that would not be expected from a lenticulostri-
ate territory infarct. The patients who did not undergo ra-
diographic follow-up were clinically well at last follow-up.
TABLE 1. Baseline clinical characteristics (n = 52)
Value
Mean age, yrs 59
Female, n (%) 39 (75)
Aneurysm location, n (%)
 ICA 21 (41)
 ACA 8 (16)
 MCA 23 (43)
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Clinical Outcomes
All patients were examined postoperatively by neuro-
surgeons and neurocritical care faculty, who made assess-
ments regarding any new neurological deficits or symp-
toms. Five patients experienced transient symptoms post-
operatively. One patient had brief aphasia after placement 
of an FD in the left MCA that resolved within 24 hours, 
with CT showing no infarct 7 days after the procedure. A 
second patient had transient aphasia and right-sided weak-
ness on postoperative day 1 after FD placement in the left 
ICA, but no infarct was noted on MRI. Three patients had 
small distal hemispheric changes on imaging, consistent 
with thromboembolic events, but no infarcts in the lenticu-
lostriate territory, and the symptoms completely resolved.
Two patients experienced transient occlusion of the 
MCA as the PED was being placed. One patient experi-
enced in-stent thrombosis during the procedure, which re-
solved with intraarterial abciximab, and had no resulting 
clinical or radiographic sequela. The other patient had an 
ACA PED that migrated proximally into the MCA, requir-
ing intraprocedural placement of an Enterprise stent (Cod-
man) in the ipsilateral MCA and treatment with intraarte-
rial abciximab (case 2, detailed below). Postprocedure CT 
scanning showed an infarct of the posterior limb of the 
ipsilateral internal capsule. The patient had hemiparesis 
postoperatively, which improved after inpatient rehabilita-
tion.
Two patients presented with hemiparesis and MCA in-
farcts due to postoperative stent occlusion. One patient was 
10 days postprocedure and had been noncompliant with 
medication; an emergency thrombectomy was performed 
successfully. There was an ipsilateral caudate infarct noted 
on MRI, but the patient was neurologically intact at the 
last follow-up. The second patient, a heavy smoker, expe-
rienced the symptoms 3 months after the procedure when 
clopidogrel was discontinued; CT scanning showed an in-
farct in the hemispheric MCA distribution but not in the 
lenticulostriate territory. Patients’ functional status other-
wise remained high, and those who had strokes improved 
over time (Fig. 1). When infarcts did occur, they were im-
mediately posttreatment or within the first 3 months (Fig. 
2).
Forty patients underwent angiography at least 6 months 
after the procedure. Complete obliteration of the aneurysm 
was seen in 29 (73%) of these patients, and incomplete oc-
clusion was seen in 11. Of the 29 patients who achieved 
complete aneurysm occlusion, the average time to com-
plete occlusion was 8.2 months.
Statistical Analysis
Univariate analysis showed that ending DAPT prior to 
6 months significantly increased the risk of stroke in the 
lenticulostriate territory (p < 0.01, OR 0.3, 95% CI 0–0.43). 
Other risk factors, including age, aneurysm location, and 
smoking status, were not significant. Multivariate analy-
sis showed that the duration of DAPT was correlated with 




A 74-year-old woman harbored an MCA aneurysm that 
was discovered on imaging workup for dementia. Angiog-
raphy showed a 10-mm right M1 aneurysm with a 5.5-mm neck arising proximal to the bifurcation, projecting supe-
riorly and anteriorly (Fig. 3). This lesion was thought to be 
appropriate for flow diversion therapy with the PED. The 
FIG. 1. Modified Rankin Scale (mRS) score at baseline and posttreatment time points up to 6 months. Figure is available in color 
online only.
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patient was maintained on DAPT prior to the procedure 
and received systematic heparin throughout the interven-
tion. A PED was deployed, starting from just proximal to 
the MCA bifurcation and ending in the supraclinoid ICA. 
The patient recovered well postoperatively and remained 
at her neurological baseline. After 1 night of observation in 
the neurointensive care unit, she was discharged home in 
good condition. The patient remained neurologically intact 
and was scheduled for her 1-year follow-up angiogram.
Case 2
A 58-year-old woman had an anterior communicat-
ing artery aneurysm that was discovered on a workup for 
headache and right-sided numbness. Angiography showed 
FIG. 2. Stroke-free clinical status from baseline to 6 months posttreatment. Figure is available in color online only.
FIG. 3. Case 1. Example of a successful treatment. A: Three-dimensional rotational angiogram showing a 10-mm right M1 aneu-
rysm with a 5.5-mm neck arising proximal to the bifurcation, projecting superiorly and anteriorly. B: Noncontrast CT image. A PED 
was deployed, starting from just proximal to the MCA bifurcation, ending in the supraclinoid ICA. The arrow indicates an infarct in 
the vascular territory supplied by the lenticulostriate vessels, which were covered by the device. Figure is available in color online 
only.
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a wide-necked, irregular, left A1/A2 junctional aneurysm, projecting posteriorly and medially (Fig. 4), which was 
thought to be amenable to flow diversion therapy with the 
PED. The patient was maintained on DAPT prior to the 
procedure and received systematic heparin throughout the 
intervention. The procedure was complicated by proximal 
device migration following deployment, encroaching on 
the M1 segment of the left MCA. This was treated with emergency placement of an Enterprise stent in the MCA 
across the PED to maintain the patency of the MCA. The 
subsequent angiogram showed platelet aggregation, which 
was treated with an intraarterial bolus of abciximab. Post-
intervention angiography showed reestablishment of brisk 
anterograde flow in both the ACA and MCA. The patient 
experienced right hemiplegia immediately postoperatively, 
which improved with time after inpatient rehabilitation. 
CT scanning showed infarcts in the left anterior frontal 
lobe and posterior limb of the left internal capsule (Fig. 4). 
At discharge, the patient was ambulating with a walker and 
able to perform activities of daily living without assistance.
Case 3
A 57-year-old woman with previously treated aneu-
rysms was found to have an enlarging right ICA commu-
nicating segment aneurysm on surveillance imaging (Fig. 
5). The patient underwent uneventful PED placement, 
with the distal end of the stent in the M1 segment. She was monitored in the neurointensive care unit and discharged 
on postoperative day 1. Ten days later, she presented to 
the emergency department with acute-onset left hemiple-
gia and was found to have complete stent occlusion. She 
had not taken clopidogrel since her discharge. She under-
went emergency thrombectomy, with postintervention re-
perfusion of the ICA and MCA. CT scanning of the head 
showed a new infarct in the lentiform nucleus (Fig. 5). She 
was restarted on a regimen of DAPT and ultimately recov-
ered full function.
Discussion
With mounting safety and efficacy data,13 flow diversion 
treatment of intracranial aneurysms is becoming increas-
ingly common, with successful series in treating small, 
complex, or distal pathologies. Here, we showed that cov-
ering the lenticulostriate vessels with FD does not lead to 
routine clinical evidence of ischemia in these territories 
in patients maintained on appropriate antiplatelet therapy.
Our series had 2 patients with clinical and radiographic 
infarcts in the lenticulostriate territory. One patient was 
noncompliant with antiplatelet therapy, emphasizing the 
importance of this regimen in patients treated with flow 
diversion, especially when small critical perforators are 
covered. Since her thrombectomy, the patient has returned 
to her neurological baseline, is taking her medication as 
prescribed, and has had no further events. The other pa-
tient had a clinical infarct in the MCA territory after place-
ment of a flow diverter in the ACA that migrated, resulting 
in platelet aggregation and transient occlusion of both ves-
sels. This patient had frontal infarcts, resulting from ACA 
occlusion distal to the lenticulostriate branches, and an in-
farct in the posterior limb of the internal capsule, likely re-
FIG. 4. Case 2. Example of a patient with small postprocedural infarcts. 
Angiogram showing a wide-necked irregular left A1/A2 junctional aneu-
rysm, projecting posteriorly and medially (A). Intraprocedural proximal 
migration of the ACA PED into the MCA occurred, requiring emergency 
placement of an Enterprise stent as seen here in the ipsilateral MCA (B). 
Figure is available in color online only. 
FIG. 5. Case 3. Example of a patient who suffered a posttreatment stroke. A: The patient had an enlarging right ICA communicat-
ing segment aneurysm on surveillance imaging (thick arrow). B: She underwent uneventful PED placement, with the distal end of 
the stent in the M1 (star), shown on this cone beam CT image. C: CT image of the head 10 days later showing a new infarct in the 
right lentiform nucleus (large arrow). Figure is available in color online only.
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sulting from M1 lenticulostriate occlusion. In our series, no patients experienced clinical or radiographic (from those 
with imaging follow-up) lenticulostriate infarct due to len-
ticulostriate coverage by an FD if their platelet inhibition 
was appropriate.
Flow diverters are designed with a low porosity that di-
minishes flow to the treated aneurysm but still allows flow 
to the side branches of the parent vessel.14 Initial animal 
studies of the PED, which is a braided mesh cylinder with 
pore sizes ranging from 0.02 to 0.05 mm2,3 showed no oc-
clusion of branch vessels covered with the device.7,9
Clinical data have suggested that covering branch ves-
sels is usually clinically well tolerated.21,27,29 Multiple se-
ries have shown that covering branches, including the oph-
thalmic artery (OphA), posterior communicating artery 
(PCoA), posterior inferior cerebellar artery (PICA), ante-
rior inferior cerebellar artery (AICA), and anterior choroi-
dal artery (AChA), do not lead to clinical sequelae (Table 
2).4,19,23,27,29 It is hypothesized that vessels with collateral 
supply (i.e., the OphA artery) are more likely to occlude, 
as there is an alternative blood supply, and demand from 
the covered vessel can diminish. Puffer et al.21 reported 
20 aneurysms in which a flow diverter covered the OphA. 
One was noticed to immediately retrograde fill from col-
laterals, while 2 displayed slowed filling. At follow-up, the 
OphA was occluded in 4 patients, with slowed filling in an 
additional 2; all patients were asymptomatic. Conversely, 
terminal vessels with no known collaterals seem to be 
more resistant to occlusion; multiple studies have shown 
that these vessels remain patent after being covered with 
an FD.19,23,27,29 These series suggest that demand through 
covered terminal vessels continues, as their territories have 
no other blood supply. This demand is sufficient to keep the 
ostia patent even when covered. However, even when oc-
clusion of the terminal vessels is slow, it appears to be well 
tolerated. In the series by Yavuz et al., 21 MCA aneurysms 
were treated, with one of the M2 segments jailed; 3 were 
occluded at follow-up, and 6 demonstrated reduced flow. 
No occlusion resulted in clinical symptoms.30
Similar to the AChA and basilar perforators, the lentic-
ulostriate vessels are terminal branches that supply critical 
structures. There are generally no anastomoses to supply 
their vascular territory, thus blood flow demand remains 
high after being covered. It is likely that this demand keeps 
the ostia patent. It is also possible that, if flow does de-
crease slowly, the ongoing demand drives the development 
of collaterals from other vessels that do not normally sup-
ply these territories. Just as aneurysms occlude over time, 
the ostia generally do not occlude immediately. If there is 
a slow decrease in flow, there is significant time to derive 
blood supply from other sources and prevent ischemia.
Despite the aforementioned encouraging series, there 
have been reports of occlusion of covered branch vessels 
after FD placement with clinical sequelae. Van Rooij and 
Sluzewski reported a lenticulostriate infarct that resulted in 
hemiparesis after placement of telescoping flow diverters 
in the proximal A1 despite appropriate antiplatelet thera-py.28 Lall et al. reported 3 cases of intraprocedural branch 
occlusion despite appropriate antiplatelet therapy. All pa-
tients were treated effectively with abciximab and recov-
ered without clinical sequelae.16 There is some suggestion 
that covering an ostium with multiple devices may increase 
the rate of occlusion, although no results have been statisti-
cally significant.21 In our series, all lenticulostriate vessels 
were covered with one device, and we do not recommend 
overlapping devices in this perforator-rich zone. It is our 
philosophy at our institution to not use multiple devices in 
regions with critical side branches; thus, the results pre-
sented here cannot be applied to those specific cases.
Previous endovascular techniques have demonstrated 
silent infarct rates from 10% to 69%,2,5,10,25 and there is 
concern that the rates of silent infarcts after flow diver-
sion treatment may be higher. A second study prospec-
tively compared 41 patients treated with FDs compared 
with standard stent embolization, evaluated by FLAIR and 
diffusion-weighted imaging (DWI) changes on MRI ob-
tained within 24 hours of the procedure. Patients undergo-
ing FD treatment were significantly more likely to exhibit 
radiographic changes than those undergoing standard stent 
treatment (54% vs 14%, p < 0.001). These changes were 
generally hemispheric and not in the territory of covered 
perforators; additionally, no patient experienced neurologi-
cal symptoms related to new lesions.24 These strokes were 
generally diffuse cortical foci of restricted diffusion and 
attributed to an embolic phenomenon, as all devices were 
placed in the cavernous to ophthalmic segments of the ICA 
and no major vessels were occluded.
Iosif et al.11 found a high rate of radiographic infarcts. 
Thirty-eight consecutive patients underwent MRI between 
24 and 48 hours after placement of an FD. DWI changes 
were seen in 92.1% of patients and were clinically signifi-
cant in only 13.1%. These changes were only seen in the 




No. of Side 
Branches Covered Covered Vessels
No. of Covered Branch 
Occlusions (modality) Ischemia
Szikora et al., 2010 18 28 OphA, PCoA, AChA, PICA, AICA 3 (angiography) 1 (periprocedural retinal 
branch occlusion)
Yavuz et al., 2014 21 21 M2 branches 3 (angiography) 0
Neki et al., 2015 20 20 AChA 0 (angiography) 0
Vedantam et al., 2015 49 74 OphA, PCoA, AChA 3 (angiography) 0
Mazur et al., 2016 11 11 PICA 1 (angiography, MRI) 0
Rangel-Castilla et al., 2017 82 127 OphA, PCoA, AChA, ACA 13 (angiography) 0
Bhogal et al., 2017 140 285 OphA, PCoA, AChA, ACA 29 (angiography) 5 (embolic on DWI MRI)
J Neurosurg January 11, 2019 7
Wagner et al.
territory of covered side branches in 22%; this was not sig-
nificantly different from the DWI findings in the distal ter-
ritory of the stented vessel. Similar to previous studies and 
our series, the majority of patients with radiographic ische-
mia showed no clinical symptoms.11 Brasiliense et al.6 also 
evaluated imaging changes in a series of patients treated 
with FDs. Fifty-nine patients were prospectively treated 
with FDs, and DWI was performed within 24 hours in all 
patients. New lesions were identified on DWI in 62.7% of 
patients; however, 21.8% of these lesions were not in the 
territory of the treated vessel, and only 5.1% of patients 
experienced neurological symptoms.6 Flow diversion cre-
ates stasis of blood flow within the aneurysm, eventually 
leading to thrombosis and occlusion; however, in the im-
mediate postprocedural time before occlusion, there is still 
flow into and out of the aneurysm. It is possible that this 
stasis allows for thrombus formation and embolization, but 
more likely that the thrombus was formed on the surface 
of these low porosity devices with subsequent emboliza-
tion, leading to the significantly higher rate of radiographic 
infarcts seen in patients treated with flow diversion than in 
those treated with standard stenting.24
The clinical significance associated with these imaging 
changes remains unknown. In our series of 51 patients, only 
3 patients had sustained neurological deficits, 2 of whom 
were noncompliant with dual antiplatelet therapy. As with 
any surgical technique, patient selection and counseling re-
main paramount. While flow diversion has revolutionized 
aneurysm treatment, it is not without risks; all surgical and 
endovascular interventions should be carefully considered 
for each individual patient. Patients who are selected for 
flow diversion are maintained on DAPTs, which are care-
fully monitored. Strict adherence to the regimen on the 
part of the patient and meticulous monitoring on the part 
of the clinical team are essential to minimize complica-
tions; as presented here, the 2 cases of in-stent thrombosis 
occurred in patients who were off DAPT. Patients must 
be extensively counseled on the importance of the DAPT 
regimen prior to intervention, especially in cases in which 
critical perforators are covered.
Study Limitations
This study is limited in its retrospective design and 
the small number of patients. Additionally, imaging was 
not performed in all patients, but rather only in those who 
demonstrated clinical symptoms. Radiographic and clini-
cal outcomes were assessed by the treating team and not 
a blinded reviewer. It is possible that a greater number of 
patients experienced radiographic infarcts in the lenticu-
lostriate territory but remained asymptomatic, and future 
studies with prospectively collected MRI and clinical out-
comes are needed to delineate this. This study is also sub-
ject to selection bias, as some patients were treated with 
FDs based on surgeon preference.
Conclusions
Flow diversion is gaining widespread used in increas-
ingly varied pathology. Here, we showed that placement of 
flow diverters in the M1 and A1 segments, covering the len-ticulostriate vessels, does not routinely lead to a clinically 
relevant perforator distribution infarct in patients who are 
appropriately inhibited with DAPT. However, larger stud-
ies with follow-up imaging are needed to corroborate our 
findings.
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